Preliminary Q4 2025 Sartorius AG and Sartorius Stedim Biotech SA Earnings Call Transcript
Key Points
- Sartorius Stedim Biotech SA (SDMHF) achieved considerable profitable growth in 2025, driven by improving demand trends, particularly for consumables.
- The company delivered results slightly ahead of its upgraded full-year 2025 sales guidance, with profitability landing in the upper half of the initial guidance.
- Strong double-digit growth in recurring revenue more than offset continued softness in equipment, which stabilized over the year.
- The company made tangible progress in innovation and partnerships, launching several new solutions across both divisions, including sustainable product designs and advanced bioanalytical tools.
- Sartorius Stedim Biotech SA (SDMHF) further reduced its leverage ratio, underscoring its commitment to financial discipline and a strong balance sheet.
- The equipment business remained soft throughout 2025, although it showed signs of stabilization in the second half of the year.
- The company faced headwinds from a weaker US dollar, which negatively impacted reported sales growth by almost 300 basis points.
- Operating cash flow decreased compared to the previous year, influenced by significant one-off inventory reduction measures in 2024.
- The lab products and services division experienced a decline in margin due to an unfavorable product mix and FX impacts.
- The company set a broad guidance range for 2026 due to continued macroeconomic and industry-specific volatility, reflecting uncertainty in market conditions.
Welcome to the presentation of Sartorius and Sarturiused in Biotext on the preliminary results 2025. Please note that the call is being recorded and streamed on Sartorius's website. Your participation in this implies you consent with this. A replay will be available shortly after the call.
I would now like to turn the conference over to Petra Muller, head of investor relations of Sartorius.
Thank you, operator. Hello and a warm welcome from my side. I'm joined today by our CEO Michel Grosse, by Florian Funk, our CFO, by Rene Faber, head of our bioprocessing division and CEO of the Torres in Biotech, and by Alexandra Gatzenmayer, head of our lab products and services division. As always, we will start with prepared remarks followed by the Q&A session. As the call is scheduled to one hour, please limit your question to one so that as many participants as possible can take part. Please note that management comments during this call will include forward-looking statements that involve risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
